{"title":"Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis","authors":"Haiyu Wang, Weihao Liang, Ling Zhou, Jiankang Song, Biao Wen, Qiaoping Wu, Yuanjian Zhang, Xiaofeng Zhang, Haoran Ke, Yujun Tang, Fuyuan Zhou, Youfu Zhu, Weiqun Wen, Zhihua Liu, Yali Ji, Qintao Lai, Qinjun He, Wenfan Luo, Tingting Qi, Miaoxia Liu, Xiaoqin Lan, Yongpeng Chen, Ranran Xi, Junting Wan, Lin Dai, Yuan Li, Jinjun Chen","doi":"10.3350/cmh.2024.0609","DOIUrl":null,"url":null,"abstract":"<p><strong>Background & aims: </strong>Cirrhotic patients with liver stiffness measurement (LSM) <20kPa and platelet count ≥150/ul (Baveno VI criteria), otherwise spleen stiffness measurement (SSM) ≤ 40kPa (Baveno VI-SSM criteria) can avoid endoscopy screening, however, no prospective data for their hepatic outcomes.</p><p><strong>Methods: </strong>Compensated cirrhosis with chronic hepatitis B were prospectively enrolled from April 2019 to April 2022 and followed until July 2023. All patients underwent LSM, SSM and esophagogastroduodenoscopy (EGD) assessment.</p><p><strong>Results: </strong>Among 1224 patients enrolled with median follow-up of 30 months (IQR 21-42), the incidence of decompensation was greater in 560 patients with unfavored Baveno-VI criteria (0.5 vs. 20.4 per 1,000 person-years, p=0.0004) than that in 664 patients with favored Baveno-VI-SSM criteria. The Baveno VI-SSM model identified more patients (54.2%) into low-risk for decompensation than Baveno VII-SSM model (single cutoff) (48.4%, p=0.004) and than Baveno VI criteria (34.6%, p<0.0001) did. Patients with high-risk varices diagnosed via endoscopy following Baveno VI-SSM model assessment had greater probability of decompensation compared to those identified by the Baveno VII-SSM model (single cutoff) (42.8 vs. 21.1 per 1,000 person-years, p=0.0088). Additionally, among the 493 patients who underwent endoscopic re-assessment, 242 patients with favored Baveno VI-SSM criteria had much lower incidence of EV progression (2.6 vs. 99.5 per 1,000 person-years, p=0.0004) and lower risk of decompensation compared to 140 patients with unfavored Baveno VI-SSM model (0 vs. 34.2 per 1,000 person-years, p=0.0256).</p><p><strong>Conclusions: </strong>Baveno VI-SSM model could identify chronic hepatitis B-related cirrhosis patients at low risk of decompensation, which was greatly improved upon Baveno VI-SSM reassessment.</p>","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":14.0000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Molecular Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3350/cmh.2024.0609","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background & aims: Cirrhotic patients with liver stiffness measurement (LSM) <20kPa and platelet count ≥150/ul (Baveno VI criteria), otherwise spleen stiffness measurement (SSM) ≤ 40kPa (Baveno VI-SSM criteria) can avoid endoscopy screening, however, no prospective data for their hepatic outcomes.
Methods: Compensated cirrhosis with chronic hepatitis B were prospectively enrolled from April 2019 to April 2022 and followed until July 2023. All patients underwent LSM, SSM and esophagogastroduodenoscopy (EGD) assessment.
Results: Among 1224 patients enrolled with median follow-up of 30 months (IQR 21-42), the incidence of decompensation was greater in 560 patients with unfavored Baveno-VI criteria (0.5 vs. 20.4 per 1,000 person-years, p=0.0004) than that in 664 patients with favored Baveno-VI-SSM criteria. The Baveno VI-SSM model identified more patients (54.2%) into low-risk for decompensation than Baveno VII-SSM model (single cutoff) (48.4%, p=0.004) and than Baveno VI criteria (34.6%, p<0.0001) did. Patients with high-risk varices diagnosed via endoscopy following Baveno VI-SSM model assessment had greater probability of decompensation compared to those identified by the Baveno VII-SSM model (single cutoff) (42.8 vs. 21.1 per 1,000 person-years, p=0.0088). Additionally, among the 493 patients who underwent endoscopic re-assessment, 242 patients with favored Baveno VI-SSM criteria had much lower incidence of EV progression (2.6 vs. 99.5 per 1,000 person-years, p=0.0004) and lower risk of decompensation compared to 140 patients with unfavored Baveno VI-SSM model (0 vs. 34.2 per 1,000 person-years, p=0.0256).
Conclusions: Baveno VI-SSM model could identify chronic hepatitis B-related cirrhosis patients at low risk of decompensation, which was greatly improved upon Baveno VI-SSM reassessment.
期刊介绍:
Clinical and Molecular Hepatology is an internationally recognized, peer-reviewed, open-access journal published quarterly in English. Its mission is to disseminate cutting-edge knowledge, trends, and insights into hepatobiliary diseases, fostering an inclusive academic platform for robust debate and discussion among clinical practitioners, translational researchers, and basic scientists. With a multidisciplinary approach, the journal strives to enhance public health, particularly in the resource-limited Asia-Pacific region, which faces significant challenges such as high prevalence of B viral infection and hepatocellular carcinoma. Furthermore, Clinical and Molecular Hepatology prioritizes epidemiological studies of hepatobiliary diseases across diverse regions including East Asia, North Asia, Southeast Asia, Central Asia, South Asia, Southwest Asia, Pacific, Africa, Central Europe, Eastern Europe, Central America, and South America.
The journal publishes a wide range of content, including original research papers, meta-analyses, letters to the editor, case reports, reviews, guidelines, editorials, and liver images and pathology, encompassing all facets of hepatology.